Press Release Archive - Corporate News

Corporate News

05.23.2013
Forest Laboratories Provides Update on Succession Planning
05.17.2013
Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference
05.16.2013
Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting
05.14.2013
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013
05.09.2013
Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure
05.01.2013
Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD
04.23.2013
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization
01.17.2013
Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension
01.15.2013
Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings
01.03.2013
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation